Australia markets closed

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3409+0.0316 (+10.22%)
At close: 04:00PM EST
0.3200 -0.02 (-6.13%)
After hours: 05:27PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.3093
Open0.3000
Bid0.3409 x 1300
Ask0.3483 x 3200
Day's range0.3000 - 0.3483
52-week range0.2720 - 3.3600
Volume242,049
Avg. volume271,540
Market cap27.206M
Beta (5Y monthly)0.31
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

    REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS). On January 20, 2022, the

  • GlobeNewswire

    Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event

    REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title:Patient Advocacy: Honing the Skill for Crossover Communicat

  • GlobeNewswire

    Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee. The independent members of the Board of Directors of Soleno approved the grant of a non-qualified stock option to purchase 75,000 shares of common stock to Michael Woloschak, S